Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C

被引：12

作者：

Nagaoki, Yuko ^{[1
]}

Imamura, Michio ^{[1
]}

Kawakami, Yoshiiku ^{[1
]}

Kan, Hiromi ^{[1
]}

Fujino, Hatsue ^{[1
]}

Fukuhara, Takayuki ^{[1
]}

Kobayashi, Tomoki ^{[1
]}

Ono, Atsushi ^{[1
]}

Nakahara, Takashi ^{[1
]}

Naeshiro, Noriaki ^{[1
]}

Urabe, Ayako ^{[1
]}

Yokoyama, Satoe ^{[1
]}

Miyaki, Daisuke ^{[1
]}

Murakami, Eisuke ^{[1
]}

Kawaoka, Tomokazu ^{[1
]}

Tsuge, Masataka ^{[1
]}

Hiramatsu, Akira ^{[1
]}

Aikata, Hiroshi ^{[1
]}

Takahashi, Shoichi ^{[1
]}

Hayes, C. Nelson ^{[1
]}

Ochi, Hidenori ^{[2
]}

Chayama, Kazuaki ^{[1
,2
]}

机构：

[1] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Gastroenterol & Metab, Hiroshima 7348551, Japan

[2] Inst Phys & Chem Res RIKEN, Ctr Genom Med, Lab Digest Dis, Hiroshima, Japan

来源：

HEPATOLOGY RESEARCH | 2014年 / 44卷 / 14期

关键词：

chronic hepatitis C; inteferon lambda 4; rapid virological response; sustained virological response; telaprevir; GENOME-WIDE ASSOCIATION; GENOTYPE; INFECTION; HEPATOCELLULAR-CARCINOMA; ITPA POLYMORPHISM; GENETIC-VARIATION; VIRAL RESPONSE; IL28B; HCV; PEGINTERFERON; VIRUS;

D O I：

10.1111/hepr.12336

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

AimThe predictive value of the recently identified interferon- (IFNL)4 polymorphism on the outcome of telaprevir (TVR), pegylated interferon (PEG IFN) plus ribavirin (RBV) combination therapy for chronic hepatitis C is unknown. MethodsWe assessed predictive factors for sustained virological response (SVR) for TVR, PEG IFN plus RBV combination therapy in 283 genotype 1 chronic hepatitis C patients. IFNL4 polymorphism ss469415590 was analyzed by Invader assay. ResultsSVR rates for patients with IFNL4 TT/TT genotype were significantly higher than for those with the IFNL4 TT/G or G/G genotypes (93% and 59%, respectively, P<0.0001). In a multivariate regression analysis, prior treatment history (treatment-naive patients or patients who relapsed during prior treatment) (odds ratio [OR], 2.385; P=0.028), rapid virological response (OR, 6.800; P<0.0001) and ss469415590 TT/TT genotype (OR, 8.064; P<0.0001) were identified as significant independent predictors for SVR. In patients with IFNL4 TT/G or G/G genotypes, SVR rates for non-RVR patients were significantly lower than RVR patients (22% and 75%, respectively, P<0.0001). ConclusionAnalysis of IFNL4 polymorphism is a valuable predictor in patients receiving TVR triple therapy.

引用

页码：E447 / E454

页数：8

共 28 条

[1] Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype1b and high viral load [J].

Akuta, N ;

Suzuki, F ;

Sezaki, H ;

Suzuki, Y ;

Hosaka, T ;

Someya, T ;

Kobayashi, M ;

Saitoh, S ;

Watahiki, S ;

Sato, J ;

Kobayashi, M ;

Arase, Y ;

Ikeda, K ;

Kumada, H .

JOURNAL OF MEDICAL VIROLOGY, 2006, 78 (01) :83-90

[2] Amino Acid Substitution in Hepatitis C Virus Core Region and Genetic Variation Near the Interleukin 28B Gene Predict Viral Response to Telaprevir with Peginterferon and Ribavirin [J].

Akuta, Norio ;

Suzuki, Fumitaka ;

Hirakawa, Miharu ;

Kawamura, Yusuke ;

Yatsuji, Hiromi ;

Sezaki, Hitomi ;

Suzuki, Yoshiyuki ;

Hosaka, Tetsuya ;

Kobayashi, Masahiro ;

Kobayashi, Mariko ;

Saitoh, Satoshi ;

Arase, Yasuji ;

Ikeda, Kenji ;

Chayama, Kazuaki ;

Nakamura, Yusuke ;

Kumada, Hiromitsu .

HEPATOLOGY, 2010, 52 (02) :421-429

[3] IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction [J].

Bibert, Stephanie ;

Roger, Thierry ;

Calandra, Thierry ;

Bochud, Murielle ;

Cerny, Andreas ;

Semmo, Nasser ;

Duong, Francois H. T. ;

Gerlach, Tilman ;

Malinverni, Raffaele ;

Moradpour, Darius ;

Negro, Francesco ;

Muellhaupt, Beat ;

Bochud, Pierre-Yves .

JOURNAL OF EXPERIMENTAL MEDICINE, 2013, 210 (06) :1109-1116

[4] IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C [J].

Chayama, Kazuaki ;

Hayes, C. Nelson ;

Abe, Hiromi ;

Miki, Daiki ;

Ochi, Hidenori ;

Karino, Yoshiyasu ;

Toyota, Joji ;

Nakamura, Yusuke ;

Kamatani, Naoyuki ;

Sezaki, Hitomi ;

Kobayashi, Mariko ;

Akuta, Norio ;

Suzuki, Fumitaka ;

Kumada, Hiromitsu .

JOURNAL OF INFECTIOUS DISEASES, 2011, 204 (01) :84-93

[5] ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C [J].

Fellay, Jacques ;

Thompson, Alexander J. ;

Ge, Dongliang ;

Gumbs, Curtis E. ;

Urban, Thomas J. ;

Shianna, Kevin V. ;

Little, Latasha D. ;

Qiu, Ping ;

Bertelsen, Arthur H. ;

Watson, Mark ;

Warner, Amelia ;

Muir, Andrew J. ;

Brass, Clifford ;

Albrecht, Janice ;

Sulkowski, Mark ;

McHutchison, John G. ;

Goldstein, David B. .

NATURE, 2010, 464 (7287) :405-408

[6] Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance [J].

Ge, Dongliang ;

Fellay, Jacques ;

Thompson, Alexander J. ;

Simon, Jason S. ;

Shianna, Kevin V. ;

Urban, Thomas J. ;

Heinzen, Erin L. ;

Qiu, Ping ;

Bertelsen, Arthur H. ;

Muir, Andrew J. ;

Sulkowski, Mark ;

McHutchison, John G. ;

Goldstein, David B. .

NATURE, 2009, 461 (7262) :399-401

[7] Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C [J].

Hayashi, N. ;

Okanoue, T. ;

Tsubouchi, H. ;

Toyota, J. ;

Chayama, K. ;

Kumada, H. .

JOURNAL OF VIRAL HEPATITIS, 2012, 19 (02) :E134-E142

[8] Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection [J].

Hezode, Christophe ;

Forestier, Nicole ;

Dusheiko, Geoffrey ;

Ferenci, Peter ;

Pol, Stanislas ;

Goeser, Tobias ;

Bronowicki, Jean-Pierre ;

Bourliere, Marc ;

Gharakhanian, Shahin ;

Bengtsson, Leif ;

McNair, Lindsay ;

George, Shelley ;

Kieffer, Tara ;

Kwong, Ann ;

Kauffman, Robert S. ;

Alam, John ;

Pawlotsky, Jean-Michel ;

Zeuzem, Stefan .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (18) :1839-1850

[9] Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection [J].

Jacobson, Ira M. ;

McHutchison, John G. ;

Dusheiko, Geoffrey ;

Di Bisceglie, Adrian M. ;

Reddy, K. Rajender ;

Bzowej, Natalie H. ;

Marcellin, Patrick ;

Muir, Andrew J. ;

Ferenci, Peter ;

Flisiak, Robert ;

George, Jacob ;

Rizzetto, Mario ;

Shouval, Daniel ;

Sola, Ricard ;

Terg, Ruben A. ;

Yoshida, Eric M. ;

Adda, Nathalie ;

Bengtsson, Leif ;

Sankoh, Abdul J. ;

Kieffer, Tara L. ;

George, Shelley ;

Kauffman, Robert S. ;

Zeuzem, Stefan .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (25) :2405-2416

[10]

Kawakami Y, 2013, ANTIVIR THER

← 1 2 3 →